دورية أكاديمية
أعرض في EDS

Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro , and in vivo evaluation.

التفاصيل البيبلوغرافية
العنوان: Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro , and in vivo evaluation.
المؤلفون: Aljaeid BM; a Department of Pharmaceutics, Faculty of Pharmacy , King Abdulaziz University , Jeddah , Saudi Arabia., El-Say KM; a Department of Pharmaceutics, Faculty of Pharmacy , King Abdulaziz University , Jeddah , Saudi Arabia.; b Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Al-Azhar University , Cairo , Egypt., Hosny KM; a Department of Pharmaceutics, Faculty of Pharmacy , King Abdulaziz University , Jeddah , Saudi Arabia.; c Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Beni-Suef University , Beni-Suef , Egypt.
المصدر: Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2019 Jul; Vol. 45 (7), pp. 1130-1139. Date of Electronic Publication: 2019 May 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 7802620 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5762 (Electronic) Linking ISSN: 03639045 NLM ISO Abbreviation: Drug Dev Ind Pharm Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Informa Healthcare
Original Publication: New York, Dekker.
مواضيع طبية MeSH: Chitosan/*analogs & derivatives , Chitosan/*chemistry , Doxazosin/*chemistry , Nanoparticles/*chemistry , Poloxamer/*chemistry , Polyphosphates/*chemistry, Administration, Oral ; Animals ; Biological Availability ; Chemistry, Pharmaceutical/methods ; Drug Carriers/chemistry ; Drug Liberation/drug effects ; Male ; Particle Size ; Rabbits ; Suspensions/chemistry
مستخلص: Objective: Control the release and enhance the bioavailability of chitosan-doxazosin mesylate nanoparticles (DM-NPs). Significance: Improve DM bioavailability for the treatment of benign prostatic hyperplasia and hypertension. Methods: Plackett-Burman design was utilized to screen the variables affecting the quality of DM-NPs prepared by ionic gelation method. The investigated variables were initial drug load (X 1 ), chitosan percentage (X 2 ), tripolyphosphate sodium (TPP) percentage (X 3 ), poloxamer percentage (X 4 ), homogenization speed (X 5 ), homogenization time (X 6 ) and TPP addition rate (X 7 ). The prepared DM-loaded NPs have been fully evaluated for particle size (Y 1 ), Zeta potential (Y 2 ), production yield (Y 3 ), entrapment efficiency (Y 4 ), loading capacity (Y 5 ), initial burst (Y 6 ), and cumulative drug release (Y 7 ). Finally, DM pharmacokinetic has been investigated on healthy albino male rabbits by means of non-compartmental analysis. Results: The combination of variables showed variability of Y 1 , Y 2 , and Y 3 equal to 122-710 nm, 3.49-23.63 mV, and 47.31-92.96%, respectively. While Y 4 and Y 5 , reached 99.87%, and 8.53%, respectively. The prepared NPs revealed that X 2 , X 3 , and X 4 are the variables that play the important role in controlling the release behavior of DM from the NPs. The in vivo pharmacokinetic results indicated the enhancement in bioavailability of DM by 7 folds compared to drug suspension and the mean residence time prolonged to 23.72 h compared to 4.7 h of drug suspension. Conclusion: The study proved that controlling the release of DM from NPs enhance its bioavailability and improve the compliance of patients with hypertension or benign prostatic hyperplasia.
فهرسة مساهمة: Keywords: Benign prostatic hyperplasia; Plackett–Burman design; chitosan; doxazosin mesylate; hypertension; ionic gelation
المشرفين على المادة: 0 (Drug Carriers)
0 (Polyphosphates)
0 (Suspensions)
0 (chitosan-tripolyphosphate)
106392-12-5 (Poloxamer)
9012-76-4 (Chitosan)
NU43IAG5BC (triphosphoric acid)
NW1291F1W8 (Doxazosin)
تواريخ الأحداث: Date Created: 20190320 Date Completed: 20191119 Latest Revision: 20191119
رمز التحديث: 20240829
DOI: 10.1080/03639045.2019.1597105
PMID: 30884977
قاعدة البيانات: MEDLINE
الوصف
تدمد:1520-5762
DOI:10.1080/03639045.2019.1597105